Which groups are suitable for larotinib/larlotinib?

Larotrectinib is a highly selective neurotrophic tyrosine receptor kinase (NTRK) fusion gene-targeting drug that is suitable for patients with a variety of solid tumors. Its main applicable population includes adult and pediatric patients diagnosed with NTRK fusion genes. Regardless of the primary site of the tumor, as long as NTRK fusion is present, they may be sensitive to the drug. This targeted therapy breaks through traditional cancer treatments and allows patients with different types of tumors to benefit from it. Especially for patients with unresectable, locally advanced or distant metastasis, larotrectinib provides them with a new treatment option.

The drug is particularly suitable for patients who have received standard treatments but have failed to respond, or whose disease has progressed due to drug resistance. Larotrectinib can be an effective later-line treatment option for individuals who have tried chemotherapy, radiation, or other targeted therapies without success. In addition, larotrectinib has also shown better efficacy for tumors in certain special locations, such as central nervous system, lung, thyroid, breast and colorectal cancer, if they carry the NTRK fusion gene.

Pediatric patients are also candidates for larotrectinib, especially when conventional treatments are limited or cannot tolerate standard treatments. Since NTRK fusion genes are common in certain childhood tumors, such as infantile fibrosarcoma, congenital mesodermal tumors and other diseases, larotrectinib provides a precise and effective treatment option for children with these rare diseases. In general, larotrectinib can be considered as a systemic treatment option for all patients who are diagnosed with NTRK fusion genes and have no better treatment options.

Reference materials:https://www.vitrakvi.com/